crossmark
Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHORecommended Treatment Guidelines A. Bekker,a H. S. Schaaf,a H. R. Draper,a L. van der Laan,a S. Murray,b L. Wiesner,c P. R. Donald,a H. M. McIlleron,c A. C. Hesselinga Desmond Tutu TB Center, Department of Pediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africaa; Department of Clinical Research, Global Alliance for TB Drug Development, New York, New York, USAb; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africac
There are limited pharmacokinetic data for use of the first-line antituberculosis drugs during infancy (
Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHORecommended Treatment Guidelines A. Bekker,a H. S. Schaaf,a H. R. Draper,a L. van der Laan,a S. Murray,b L. Wiesner,c P. R. Donald,a H. M. McIlleron,c A. C. Hesselinga Desmond Tutu TB Center, Department of Pediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africaa; Department of Clinical Research, Global Alliance for TB Drug Development, New York, New York, USAb; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africac
There are limited pharmacokinetic data for use of the first-line antituberculosis drugs during infancy (
